Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.38 |
| ▸ | SQLE | Q14534 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663788 | 1.00 | KMT2A (0.42) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL1486008 | 0.86 | KMT2A (0.34) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL11443586 | 0.83 | KMT2A (0.41) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL9244268 | 0.83 | KMT2A (0.46) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL11443587 | 0.83 | KMT2A (0.41) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL2627756 | 0.80 | BTN3A1 (0.45) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL7174933 | 0.79 | TSHR (0.65) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL28246381 | 0.79 | KMT2A (0.38) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL21936846 | 0.79 | TSHR (0.65) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL3699306 | 0.79 | KMT2A (0.46) | KMT2AALOX15MAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208024-B2 | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170260168-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA, INC. | 2017-09-14 | — | — | US | disclosed |
| EP-2203512-A1 | THERMOPLASTIC OLEFIN COMPOSITION WITH IMPROVED HEAT DISTORTION TEMPERATURE | Dow Global Technologies Inc. (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009042602-A1 | THERMOPLASTIC OLEFIN COMPOSITION WITH IMPROVED HEAT DISTORTION TEMPERATURE | DOW GLOBAL TECHNOLOGIES INC (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208024-B2 | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases | FGFR1, FGFR2, FGFR3 | KMT2A 594/4885ALOX15 4449/4885MAPT 3292/4885 |
| US-20170260168-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR2, FGFR3 | KMT2A 594/4885ALOX15 4449/4885MAPT 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.